Virtual drug screening for prion diseases: A valuable step?  by Cordeiro, Yraima
EBioMedicine 9 (2016) 15–16
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryVirtual drug screening for prion diseases: A valuable step?Yraima Cordeiro
Faculty of Pharmacy, Federal University of Rio de Janeiro, BrazilDOI of original article: http://dx.doi.org/10.1016/j.ebi
E-mail address: yraima@pharma.ufrj.br.
http://dx.doi.org/10.1016/j.ebiom.2016.06.043
2352-3964/© 2016 Published by Elsevier B.V. This is an opa r t i c l e i n f oArticle history:
Received 27 June 2016
Accepted 28 June 2016
Available online 30 June 2016
Keywords:
lowing in vitro (cell assays and others) and in vivo (treatment of infected
murine or hamster models) assays.
The work from Daisuke Ishibashi and coworkers proposes a high-
throughput docking procedure to funnel the selection of possible anti-
scrapie compounds from a huge library of organic compounds
(Ishibashi et al., 2016). The group used a structure-based drug discoveryPrion diseases
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Spongiform encephalopathy
Prion proteinThe search for effective drugs against transmissible spongiform
encephalopathies (TSEs) and other protein misfolding diseases is still
a major challenge for those pursuing a therapy for such devastating
diseases. The relative inefﬁcacy of all compounds used so far in clinical
assays may be due to the lack of knowledge about the relevant molecu-
lar target (or targets) for prion diseases and/or different prion strains.
Limited pharmacokinetic properties (such as the inability to cross the
blood brain barrier), along with signiﬁcant toxicity also imply that
from the hundreds of thousands of compounds investigated in vitro
for anti-scrapie activity so far, only a fewhave proven valuable in animal
models of TSEs. High-throughput screening of organic compounds for
anti-prion activity is time- andmoney-consuming, as it usually employs
as the initial step compound-screening in scrapie-infected cell lines.
Effective compounds selected in this step are those that signiﬁcantly re-
duce the amount of PrPRes (prion protein resistant to proteases) in these
cells after lysis and digestion with proteinase K (Kocisko and Caughey,
2006). Other groups propose that an initial in silico step that investigates
the drug interaction with the prion protein would improve prediction
and selection of most important anti-scrapie compounds based on a
PrP binding score (Hosokawa-Muto et al., 2009; Hyeon et al., 2015). In
this case, compounds with high binding scores (docking energy) forom.2016.06.010.
en access article under the CC BY-NCthe highly conserved PrP globular domain will be selected for the fol-
algorithm in theDEGIMA supercomputer that allowed rapid selection of
prion protein ligands that were further evaluated in vitro and in vivo
regarding their suitability as anti-scrapie drugs. The drug-selection cri-
terion used was binding to the prion protein ‘hot-spot’ region using, as
a reference, the binding afﬁnity of GN8 compound, described by Kuwata
and coworkers (Kuwata et al., 2007), in a similar approach as that pre-
viously described (Hyeon et al., 2015). This work is substantial for
basic research and the clinic as it proposes a virtual screening approach
that can then be validated using in vitro and in vivo assayswith prion in-
fected animals. In this case, there is economy of time and costs, as only
compounds revealed by the docking simulation that interact with the
PrP pocket, previously shown as the binding-site for other anti-scrapie
compounds (Kuwata et al., 2007; Ferreira et al., 2014), will be synthe-
sized and further evaluated. Validation of compound interaction with
PrP was carried out by surface plasmon resonance (SPR) assays
(Ishibashi et al., 2016). In a similar experimental approach, a platform
was recently created to unify the docking simulation, MD simulation
and quantum chemistry calculations, named NAGARA (Ma et al.,
2016). This platform was applied to the discovery of novel anti-prion
compounds, using as the initial step docking simulations with the glob-
ular domain of murine PrP (PDB: 1AG2).
However, onemight question whether effective compounds that do
not bind to the C-terminal domain of PrP or that have other molecular
targets besides PrP (Poncet-Montange et al., 2011) will be excluded
from this virtual screening. In the ﬁrst case, docking with at least the
90–231 domain of the prion protein will prove useful. Besides, if PrPSc
is the target for such compounds, there is an urgent need to address
the three-dimensional structure of the most abundant (or repetitive
structure) for the PrPSc aggregates (Requena andWille, 2014). Molecu-
lar dynamics simulations indicated that parallel in-register intermolec-
ular β-sheet architecture can be formed by PrPSc (Groveman et al.,
2014) and the use of a supercomputer (no longer for high-throughput
screening) may allow identiﬁcation of compounds that bind to PrPSc.
That said, this is no easy challenge, and deserves attention from the
scientiﬁc community, and especially biophysicists and computational-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
16 Y. Cordeiro / EBioMedicine 9 (2016) 15–16biologists. Taking into account that the interaction of a compound with
a speciﬁc region of the prion protein globular domain is a prerequisite
for effective anti-scrapie activity (what is not always the case, as
discussed above) the work published in EBioMedicine provides a
straightforward screening approach. In particular, it allows selection of
compounds with IC50 values in the micromolar range from a library of
more than 200,000 molecules. Although effective for different prion
strains in infected-cells lines, the selected compounds did not increase
survival of prion-infected mice (Ishibashi et al., 2016). This result
reinforces the need for a thorough pharmacokinetic assessment of the
most promising molecules. In general, this approach by may prove
useful to screen for drugs against other diseases, mainly for those with
a deﬁned molecular target and a previously characterized binding
region in the target protein.
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